Drug delivery device
AssigneeAmgen Inc.
InventorsLawrence S. Ring, Dhairya Mehta, Stephanie Toy, Ferry Tamtoro, Alexander Stuart Cairns, Scott R. Gibson
Life of this patent
Estimating the term…
Abstract
A drug delivery device includes a blunt cannula and a reservoir. The blunt cannula has a cylindrical wall that defines an axial passage between a first end and a second end of the blunt cannula. The wall has at least a first tapered region at the first end to define an opening in fluid communication with the axial passage and adapted at the first end to resist interruption of fluid flow through the axial passage and out of the first end of the blunt cannula. The reservoir is connected to the second end of the blunt cannula.
Claims24
A wearable on-body drug delivery device comprising:
- a housing having an opening;
- an adhesive for attaching the wearable on-body drug delivery device to skin of a patient;
- a reservoir disposed in the housing;
- a volume of a drug disposed in the reservoir, the drug comprising a granulocyte colony-stimulating factor (G-CSF);
- a cannula having a cylindrical wall that defines an axial passage between a first end and a second end of the cannula, the first end of the cannula disposed within the housing in an initial state and subsequently disposed through the opening in the housing for insertion into the patient in a delivery state;
- a hub coupled with the second end of the cannula;
- an introducer needle disposed at least partially in the cannula and configured to move relative to the cannula;
- a second needle configured to facilitate fluid communication between the reservoir and the cannula in the delivery state;
- and
- wherein the cannula defines at least one bend forming an obtuse angle.
A method comprising:
- attaching a wearable on-body drug delivery device to a patient's skin with an adhesive;
- the wearable on-body drug delivery device automatically inserting a cannula into the patient's skin using an introducer needle, the cannula having a cylindrical wall that defines an axial passage between a first end and a second end of the cannula, wherein the cannula defines at least one bend forming an obtuse angle, wherein a hub is coupled with the second end of the cannula, wherein a reservoir is included in the wearable on-body drug delivery device at least when the wearable on-body drug delivery device inserts the cannula into the patient's skin, and wherein the wearable on-body drug delivery device comprises a second needle configured to facilitate fluid communication between the reservoir and the cannula;
- and
- delivering a volume of a drug disposed in the reservoir into the patient, the drug comprising a granulocyte colony-stimulating factor (G-CSF).
Dependencies are inferred from the claim text.